

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 25, 2015

Rennova Health, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

001-35141  
(Commission File Number)

68-0370244  
(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida  
(Address of Principal Executive Offices)

33401  
(Zip Code)

(561) 855-1626  
(Registrant's Telephone Number, Including Area Code)

\_\_\_\_\_  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

Attached to this report as Exhibit 99.1 is a presentation that Rennova Health, Inc. (the “Company”) will present at the LD MICRO Main Event Conference at the Luxe Sunset, Los Angeles, CA on December 2, 2015.

Also attached to this report as Exhibit 99.2 is a press release issued by the Company on November 25, 2015 announcing the Company’s participation in the conference.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, and any information presented at the conference, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d)

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	Presentation slides.
99.2	Press Release, dated November 25, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 30, 2015

RENNOVA HEALTH, INC.

/s/ Seamus Lagan

Seamus Lagan  
Chief Executive Officer  
(principal executive officer)

---


## EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Exhibit Description</b>
99.1	Presentation slides.
99.2	Press release, dated November 25, 2015.

# RennovaHealth

Solutions Driven By Innovation

Nasdaq: RNVA



## Forward Looking Statements and Non-GAAP Information

This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combined businesses, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.

Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 16 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

# RennovaHealth

Solutions Driven By Innovation

NASDAQ: RNVA

Listed on Nasdaq on November 3<sup>rd</sup> 2015  
after completion of a merger between  
Medytox Solutions, Inc. and CollabRx, Inc.



OTCBB since 2011 (MMMS)




Nasdaq listed since 1995  
CollabRx since 2012 (CLRXX)

- We are four years into our business plan with a number of significant milestones already achieved
- We have revenue – Medytox had \$58 million of sales in 2014
- Our operations are profitable, with Medytox having positive adjusted EBITDA of \$18.2 million in 2014
- We operate in a sizable and established market place
- We have a capable management team
- We have a solid foundation from which we can grow

Rennova Health, Inc. is a vertically integrated company that provides industry leading Diagnostics and supportive software solutions to healthcare providers.

Rennova Health owns and operates five high-complexity CLIA and CAP certified laboratories strategically located across the U.S





## Rennova Health, Inc. offers a single source solution for Medical Providers

The diagnostics sector has changed dramatically in the last few years

Medical providers need more than just diagnostics

### **They need:**

- Efficient and easy ordering and reporting
- Electronic health records
- Seamless integration
- Revenue Cycle Management
- Funding and financial solutions
- Interpretation of diagnostics


### **Rennova products:**

- Medytox Advantage
- Medical Mime
- Clinlab
- Medical Billing Services
- Platinum Financial Solutions
- CollabRx

Medical providers need an increasing number of integrated and interoperable solutions to enable their business to function


# Our Brands

Our solutions can be stand alone or integrated



# RennovaHealth

Solutions Driven By Innovation



\* In progress

## Drug and Alcohol Rehabilitation

- Total Market Size – estimated at \$35 Billion\*
  - Large and growing number of facilities in a fragmented market
  - Between 14,500 to 16,700 outpatient clinics\*
- Market growth from high demand:
  - Over 23 million Americans are addicted to alcohol and other drugs\*\*
  - The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million\*\*\*
  - 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform\*\*\*\*

## Pain Management Sector

- Total Market Size – estimated at \$2-\$4 billion\*\*\*\*\*
- Large and growing number of clinics in a fragmented market
  - Private clinics in the U.S. estimated between 1,500 to 2,500
  - More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication
- Market growth from high demand:
  - Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population\*\*\*\*\*  
Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life\*\*\*\*\*
  - Between 5 to 8 million people use opioids for long-term pain management
  - In 2012, U.S. providers wrote 259 million prescriptions for opioid painkillers\*\*\*\*\*

## Market Drivers

### Lab Services Drivers

- Secular growth
- Compliance


### Value-added services

- Efficiency
- Cost
- Revenue cycle management

Sources:  
\*IBIS World,  
\*\*The National Council on Alcoholism and Drug  
Dependency,  
\*\*\*SAMHSA,  
\*\*\*\*National Association of Alcoholism and Drug  
Abuse Counselors  
\*\*\*\*\*The U.S. Addiction Rehab Market, Bharat  
Publication,  
\*\*\*\*\*NIH,  
\*\*\*\*\*CDC and Pain Physician Publication.

# History

Pre-merger numbers from Medytex




**2015 Revenue 9 months: \$42.6M**  
Diagnostics represents >95% of our revenue

**Transition year**

- **Investment in Labs**
- **Investment in software**
- **Merger costs**
- **Billing Company restructure**
- **Toxicology sector**
  - **Additional scrutiny by payers and slower payments caused by many Labs who had adopted fraudulent practices**

**Overhead, merger and investment costs will outweigh profit from operations for 2015**

**Jan-Sept 2015**



## Capital Structure

13,763,275 common shares outstanding as of 11/19/2015

### Preference Shares

5,000 shares of Series B Preference shares

These shares convert to 1,146,789 additional shares of common stock on Dec 31<sup>st</sup> each year for five years

Total = 5,733,945 additional common shares over five years

\$360,000 of convertible preferred shares from an acquisition that will convert to common shares before Sept 2016

Warrants 446,947 warrants to purchase shares at \$9.40

Options	\$4.80	467,000
	\$5.00	7,800,000
	\$6.11	970,800
	\$7.50	18,467
	\$9.40	446,947
	\$9.77	325,600
	\$10.00	7,000,000
	\$10.50	1,250
	\$15.00	1,000
	\$19.90	8,658
	>\$20	29,900

**Fully diluted  
(if all options are exercised)**

**at \$5.00 is estimated 27M  
at \$10.00 is estimated 34M**

**Debt of approximately \$6M  
Receivables of approximately \$22M  
(Medytox at November 25<sup>th</sup> 2015)**

## Management:

- **Seamus Lagan**                      **CEO**  
20 years experience in the restructuring, development and management of startup and small companies
- **Jason Adams**                      **CFO**  
CFO of public companies and in behavioral health sector
- **Sebastien Sainsbury**              **Investor Relations**  
Banking and wealth management and 10 years on the Board of AIG International
- **Steven Burdelski**                  **Chief Compliance Officer**  
25 years with the FBI with responsibility for corporate and legal compliance to improve performance
- **Frank Dias**                          **Business Development and Sales**  
Entrepreneur with 25 years experience in sales and logistics
- **Tiffany Vandemark**                **Marketing Director**  
15 years in marketing. Oversaw the launch and first four years of Chobani (Greek yogurt)
- **Dr. William DePond**                **COO of Lab Operations and CEO of each Lab**  
Board certified in Anatomic and Clinical Pathology with years in management for Quest owned Labs
- **Dean Viskovich**                    **In-House counsel**  
25 years experience as a trial and defense attorney in the healthcare sector
- **Charles Darcy**                      **Compliance Officer**  
COO in hospitals with Bachelors degree in Laboratory Science and Masters degree in Health Administration



**Board:**

- **Thomas Mika** Chairman of Rennova, CEO of CollabRx (subsidiary)  
10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard
- **Seamus Lagan** CEO  
20 years experience in the restructuring, development and management of startup and small companies. Founder, investor and largest shareholder in what is now Rennova
- **Christopher Diamantis** Director  
Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm. Acts as Chairman and a director of a number of Banks
- **Michael Goldberg** Director  
16 years as CEO of an AMEX-listed healthcare company that acquired 23 labs and 2 hospitals under his tenure
- **Dr. Paul Billings** Director  
A nationally recognized expert on genomic and precision medicine. Has served as Chief Medical Officer or Director of some of the nation's largest health care companies
- **Benjamin Frank** Director  
Retired lawyer and businessman who served as Chairman of the Board of the Healthcare District of Palm Beach County
- **Robert Lee** Director  
16 years as a Managing Director of Morgan Stanley Dean Witter and Managing Director of the M&A group at Morgan Stanley, where he worked closely with financial sponsors. Chairman of numerous audit committees

## Foundation to grow from

...we are able to grow our core diagnostics business from a position of strength and to expand into the more complex, higher-margin clinical diagnostics

... we can aggressively acquire the customers, licenses or business of cash-strapped, failing diagnostic labs of all sizes

...our expertise allows us to identify and vet prospects for the quality and integrity of their licenses, payor relationships, receivables and customers

...our information technology solutions allow for seamless integration of customer or company acquisitions, to improve efficiency, and to exercise continuous control

...our unblemished record for compliance in all aspects of our business will attract the best of customers, companies and partners

## Current focus

Expand our current lab business accross the nation	Ongoing
Capitalize on the disruption in the toxicology industry	Ongoing
Add additional tests and methodologies to our menu	Ongoing
Roll out our EHR product	Launched Oct
Roll out our Medical Billing Services	Launch underway
Implement our Financial services solution	Next 12 months
Infrastructure	
Analytics	

## Current projects

Self directed testing	In progress
Collection solution	1st half of 2016
Added value interpretation	1st half of 2016
Cancer diagnostics	1st half of 2017
Epindex	
Point of care test for Diabetes	2 year project

**Reconciliation of GAAP to Adjusted Measures - Medytox Solutions, Inc. Pre Merger**

<i>(in thousands)</i>	2011	2012	2013	2014	Jan-Sep 2015
Net Revenue	\$ 3,993	\$ 21,076	\$ 41,889	\$ 57,928	\$ 28,921
Write-off of Receivables Aged Greater Than One Year	-	-	-	-	13,299
<b>Adjusted Revenue</b>	<b>\$ 3,993</b>	<b>\$ 21,076</b>	<b>\$ 41,889</b>	<b>\$ 57,928</b>	<b>\$ 42,220</b>
Net Income	\$ 587	\$ 2,747	\$ 7,820	\$ 8,260	\$ (7,079)
Provision for Income Taxes	(172)	481	5,569	7,561	(2,580)
Interest Expense	175	654	475	514	1,595
Depreciation and Amortization	18	66	408	1,500	1,979
EBITDA	608	3,948	14,272	17,835	(6,085)
Write-off of Receivables Aged Greater Than One Year	-	-	-	-	13,299
Stock Compensation Expense	13	235	63	343	3,381
Merger, Acquisition and Integration Costs	-	-	-	-	925
<b>Adjusted EBITDA</b>	<b>\$ 621</b>	<b>\$ 4,183</b>	<b>\$ 14,335</b>	<b>\$ 18,178</b>	<b>\$ 11,520</b>

## Contact Us

Renova Health, Inc.  
400 South Australian Avenue  
8th Floor  
West Palm Beach, FL 33401

Phone: 844-RENOVA  
Email: [info@renovahealth.com](mailto:info@renovahealth.com)  
[www.renovahealth.com](http://www.renovahealth.com)

November 25, 2015



## **Rennova Health to Present at the LD Micro Main Event**

**WEST PALM BEACH, FL / ACCESSWIRE / November 25, 2015** / Rennova Health, Inc. (NASDAQ: RNVA), a company that provides industry leading diagnostics and supportive software solutions to healthcare providers, today announced that it will be presenting at the 8th annual LD Micro Main Event on December 2nd at 10:30 AM PST/1:30 PM EST. Seamus Lagan, Chief Executive Officer of Rennova Health, will be giving the presentation and meeting with investors.

A live audio webcast of Mr. Lagan's presentation will be available in the investor section of Rennova Health's website, [www.renovahealth.com](http://www.renovahealth.com), where it will also be archived for 90 days.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies in the small/micro-cap space.

### **About Rennova Health**

Rennova Health (Nasdaq: RNVA) owns and operates five diagnostics laboratories across the United States that provide clinical testing services specializing in toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. It offers its customers a complete, turnkey software product including: a proprietary laboratory ordering and reporting application, an advanced laboratory information management system, electronic health records, and an industry-leading platform for interpreting and reporting complex test results to physicians. Rennova's software is differentiated from that of its competitors by the breadth of its services, each of which is branded separately and is made available to physician groups in whole or in part. The software permits efficient and easy ordering and reporting, electronic health records integration, medical billing services and compliance, and diagnostic interpretation. For more information see [www.renovahealth.com](http://www.renovahealth.com).

### **About LD Micro**

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a nonregistered investment advisor. For more information, please contact 408-457-1042 or visit [www.ldmicro.com](http://www.ldmicro.com).

### **Investors**

LHA  
Kim Golodetz ([kgolodetz@lhai.com](mailto:kgolodetz@lhai.com))  
(212) 838-3777  
Or  
Bruce Voss([bvoss@lhai.com](mailto:bvoss@lhai.com))  
(310) 691-7100

SOURCE: Rennova Health